JP7706458B2 - 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体 - Google Patents

腎疾患の治療に使用するための抗αｖβ８インテグリン抗体 Download PDF

Info

Publication number
JP7706458B2
JP7706458B2 JP2022545136A JP2022545136A JP7706458B2 JP 7706458 B2 JP7706458 B2 JP 7706458B2 JP 2022545136 A JP2022545136 A JP 2022545136A JP 2022545136 A JP2022545136 A JP 2022545136A JP 7706458 B2 JP7706458 B2 JP 7706458B2
Authority
JP
Japan
Prior art keywords
antibody
renal
αvβ8 integrin
αvβ8
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022545136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511686A (ja
JP2023511686A5 (https=
JPWO2021151889A5 (https=
Inventor
ジェイムズ ベイカー，デイビッド
クレア ヒースマン，ステファニー
マルセラ エレラ，マリア
マリン，エレナ リアルテ
パトリシア モレノ－クイン，キャロル
アン マリー，リン
ツイ，ピン
ウー，ヤンリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2023511686A publication Critical patent/JP2023511686A/ja
Publication of JP2023511686A5 publication Critical patent/JP2023511686A5/ja
Publication of JPWO2021151889A5 publication Critical patent/JPWO2021151889A5/ja
Application granted granted Critical
Publication of JP7706458B2 publication Critical patent/JP7706458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022545136A 2020-01-27 2021-01-26 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体 Active JP7706458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966258P 2020-01-27 2020-01-27
US62/966,258 2020-01-27
PCT/EP2021/051753 WO2021151889A1 (en) 2020-01-27 2021-01-26 ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

Publications (4)

Publication Number Publication Date
JP2023511686A JP2023511686A (ja) 2023-03-22
JP2023511686A5 JP2023511686A5 (https=) 2024-01-23
JPWO2021151889A5 JPWO2021151889A5 (https=) 2024-01-23
JP7706458B2 true JP7706458B2 (ja) 2025-07-11

Family

ID=74561850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545136A Active JP7706458B2 (ja) 2020-01-27 2021-01-26 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体

Country Status (18)

Country Link
US (1) US20230112035A1 (https=)
EP (1) EP4096785A1 (https=)
JP (1) JP7706458B2 (https=)
KR (1) KR20220132567A (https=)
CN (1) CN115151305A (https=)
AR (1) AR121193A1 (https=)
AU (1) AU2021213403B2 (https=)
BR (1) BR112022014633A2 (https=)
CA (1) CA3167390A1 (https=)
CL (1) CL2022001999A1 (https=)
CO (1) CO2022011661A2 (https=)
CR (1) CR20220392A (https=)
EC (1) ECSP22066085A (https=)
IL (1) IL294814A (https=)
MX (1) MX2022009165A (https=)
PH (1) PH12022551863A1 (https=)
TW (1) TWI854088B (https=)
WO (1) WO2021151889A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
TW202446789A (zh) * 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520173A (ja) 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαｖβ８中和抗体
JP2015501285A (ja) 2011-08-17 2015-01-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンα−ｖβ−８と結合する抗体
JP2017522289A (ja) 2014-06-17 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたα−Ｖβ−８抗体
WO2018227018A1 (en) 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA3112523A1 (en) * 2018-08-08 2020-02-13 The General Hospital Corporation Integrin antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520173A (ja) 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαｖβ８中和抗体
JP2015501285A (ja) 2011-08-17 2015-01-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンα−ｖβ−８と結合する抗体
JP2017522289A (ja) 2014-06-17 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたα−Ｖβ−８抗体
WO2018227018A1 (en) 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Also Published As

Publication number Publication date
CR20220392A (es) 2022-09-07
CO2022011661A2 (es) 2022-08-30
CN115151305A (zh) 2022-10-04
TW202140554A (zh) 2021-11-01
JP2023511686A (ja) 2023-03-22
PH12022551863A1 (en) 2024-01-03
AU2021213403B2 (en) 2025-04-10
WO2021151889A1 (en) 2021-08-05
TWI854088B (zh) 2024-09-01
KR20220132567A (ko) 2022-09-30
ECSP22066085A (es) 2022-09-30
CA3167390A1 (en) 2021-08-05
MX2022009165A (es) 2022-08-16
EP4096785A1 (en) 2022-12-07
AU2021213403A1 (en) 2022-09-15
BR112022014633A2 (pt) 2022-09-13
AR121193A1 (es) 2022-04-27
IL294814A (en) 2022-09-01
CL2022001999A1 (es) 2023-01-27
US20230112035A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
JP7706458B2 (ja) 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体
US10202454B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
EP3645040A1 (en) Use of anti-fam19a5 antibodies for treating cancers
US9562096B2 (en) Anti-ROBO4 antibody
EP3527225A1 (en) Composition containing anti-robo4 antibody and other agents
JP2023528002A (ja) Ｔ細胞を選択的に調節するための二重特異性分子
US9416189B2 (en) Anti-CXADR antibody
TW201946658A (zh) 抗ｇｉｔｒ抗體及其用途
JP2022169737A (ja) 抗ｒａｍｐ２抗体
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК
WO2026078647A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
JP2015199725A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬
HK1207093B (en) Anti-robo4-antibody
JP2015199724A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬
JP2015196667A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250701

R150 Certificate of patent or registration of utility model

Ref document number: 7706458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150